Should I Buy PCVX? PCVX 2026 Analysis

Should You Buy Vaxcyte Inc (PCVX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

52.820

1 Day change

2.82%

52 Week Range

92.580

Analysis Updated At

2026/01/26

Vaxcyte Inc (PCVX) is not a strong buy for a beginner, long-term investor at this moment. While the company shows promising developments in its vaccine pipeline and has positive analyst sentiment, the financial performance remains weak with no revenue and significant losses. Additionally, the technical indicators suggest a mixed trend, and there are no strong trading signals or significant catalysts to justify immediate entry. It is better to monitor the stock for further developments, especially regarding its Phase 3 trial progress and financial improvements.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. Moving averages (SMA_5 > SMA_20 > SMA_200) are bullish, and the RSI is neutral at 73.179. However, the stock price has declined recently (-2.04% regular market change, -1.19% post-market change), and the next month's trend suggests a potential -4.72% decline. Key resistance levels are at 54.097 and 56.803, while support levels are at 45.333 and 42.627.

Options Data

Neutral

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The open interest put-call ratio of 1.03 indicates a balanced sentiment, while the option volume put-call ratio of 0.38 suggests higher call volume, reflecting a slightly bullish sentiment. However, implied volatility is low (IV percentile 6.8), and there is no significant options activity to indicate strong trading interest.

Technical Summary

Sell

Buy

Positive Catalysts

Initiation of Phase 3 OPUS-2 trial for VAX-31, targeting a large participant pool with promising protection rates (95% against invasive pneumococcal disease).
Analyst upgrades with a price target increase to $110 and inclusion in the Needham Conviction List.
Planned $1 billion investment in a custom fill-finish line, indicating long-term growth potential.

Neutral/Negative Catalysts

Weak financial performance with no revenue and significant net losses (-$212.83M in Q3 2025).
Recent price decline (-2.04% regular market, -1.19% post-market) and potential for further short-term downside (-4.72% in the next month).
No significant hedge fund, insider, or congress trading activity to support confidence in the stock.

Financial Performance

In Q3 2025, Vaxcyte reported no revenue growth (0% YoY) and a net loss of -$212.83M, though the loss improved by 106.38% YoY. EPS also improved to -1.56 (up 87.95% YoY). Gross margin remains at 0%. The financials indicate progress in reducing losses but highlight the lack of revenue generation.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on Vaxcyte, with Needham raising the price target to $110 and adding the stock to its Conviction List. The firm's top pick for 2026 is based on strong Phase 2 data for VAX-31 and expectations for Phase 3 success. Mizuho is also positive on the company's PCV franchise, including VAX-31 and VAX-24, which have the potential to improve existing pneumococcal vaccines.

6 Analyst Rating

Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 104.8 USD with a low forecast of 50 USD and a high forecast of 163 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 51.370

Low

Averages

104.8

High

163

Current: 51.370

Low

Averages

104.8

High

163

Needham

Joseph Stringer

Buy

upgrade

$90 -> $110

AI Analysis

2026-01-07

Reason

Needham

Joseph Stringer

Price Target

$90 -> $110

AI Analysis

2026-01-07

upgrade

Buy

Reason

Needham analyst Joseph Stringer raised the firm's price target on Vaxcyte (PCVX) to $110 from $90 and keeps a Buy rating on the shares. The analyst added Vaxcyte to the Needham Conviction List, replacing Phathom Pharmaceuticals (PHAT). Vaxcyte is the firm's top pick for 2026. It is e bullish on the shares 2026 based on the view that the "strongly positive" VAX-31 Phase 2 adult data provided "reasonably good de-risking" for the Phase 3 pivotal readout in Q4. Vaxcyte's pneumococcal vaccine still has best-in-class potential, the analyst tells investors in a research note.

Mizuho

Salim Syed

maintain

2026-01-05

Reason

Mizuho

Salim Syed

Price Target

2026-01-05

maintain

Reason

Mizuho analyst Salim Syed said the firm is positive on Vaxcyte after the U.S. Department of Health and Human Services approved a revised childhood and adolescent immunization schedule, though there is no change to the pneumococcal conjugate vaccine schedule for children. The Fly notes that Vaxcyte's PCV franchise comprises of both VAX-31 and VAX-24, both of which the company says have the potential to improve upon existing pneumococcal vaccines.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PCVX

Unlock Now

PCVX Should I Buy

PCVX Should I Buy

Should You Buy Vaxcyte Inc (PCVX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch